-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: valley of death
Commercialization and Job Creation in the Biotechnology Sector
It’s tough presenting programs on technology transfer because so much has already been said that it’s hard to find something new. However, that was not a problem this week in San Francisco at the BIO Technology Transfer Symposium. The Symposium began with an overview of the efforts by the Obama Administration to spur innovation including funding macro and micro grants to encourage the development of regional technology clusters, and proof of concept centers to help Read More >
Debunking the Myth: ‘Gene Patents’ are not necessary for healthcare innovation.
Myth: ‘Gene Patents’ are not necessary for health care innovation. Facts: Patents on DNA preparations or sequences are often the first patents upon which a later technology platform or portfolio is built. These patents are often in-licensed from universities by small start-up companies for the purpose of additional R&D, evidencing that the public/non-profit university sector cannot bear alone the cost of development of these inventions into useful products. It is precisely these types of early-stage companies Read More >
BIO Pacific Rim Summit: Status of Cellulosic Ethanol Commercialization
Qteros, ZeaChem and Verenium presented updates on their efforts to bring three unique cellulosic ethanol processes to commercial status. Qteros CTO Kevin Gray described how the company’s Q Microbe™ (Clostridium phytofermentans) enables a single step (consolidated bioprocessing) conversion and fermentation process for fuels. This approach can save as much as 40 percent in production costs. Qteros is currently scaling its technology up for a 100 liter laboratory bioreactor. ZeaChem President and CEO Jim Imbler outlined Read More >
